325 related articles for article (PubMed ID: 12746765)
1. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.
Rex JH; Pappas PG; Karchmer AW; Sobel J; Edwards JE; Hadley S; Brass C; Vazquez JA; Chapman SW; Horowitz HW; Zervos M; McKinsey D; Lee J; Babinchak T; Bradsher RW; Cleary JD; Cohen DM; Danziger L; Goldman M; Goodman J; Hilton E; Hyslop NE; Kett DH; Lutz J; Rubin RH; Scheld WM; Schuster M; Simmons B; Stein DK; Washburn RG; Mautner L; Chu TC; Panzer H; Rosenstein RB; Booth J;
Clin Infect Dis; 2003 May; 36(10):1221-8. PubMed ID: 12746765
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.
Rex JH; Bennett JE; Sugar AM; Pappas PG; van der Horst CM; Edwards JE; Washburn RG; Scheld WM; Karchmer AW; Dine AP
N Engl J Med; 1994 Nov; 331(20):1325-30. PubMed ID: 7935701
[TBL] [Abstract][Full Text] [Related]
3. [Current treatment of candidemia in non-neutropenic patients. Amphotericin B or fluconazole? A retrospective study of 62 consecutive patients].
Cobo Reinoso P; Aguado García JM; Lumbreras Bermejo C; Pérez Vela JL; Caballero Cubedo R; Sanz Sanz F; Noriega Rodríguez AR
Rev Clin Esp; 1997 Dec; 197(12):799-803. PubMed ID: 9477669
[TBL] [Abstract][Full Text] [Related]
4. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis.
Pappas PG; Chetchotisakd P; Larsen RA; Manosuthi W; Morris MI; Anekthananon T; Sungkanuparph S; Supparatpinyo K; Nolen TL; Zimmer LO; Kendrick AS; Johnson P; Sobel JD; Filler SG
Clin Infect Dis; 2009 Jun; 48(12):1775-83. PubMed ID: 19441980
[TBL] [Abstract][Full Text] [Related]
5. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.
Pappas PG; Rex JH; Lee J; Hamill RJ; Larsen RA; Powderly W; Kauffman CA; Hyslop N; Mangino JE; Chapman S; Horowitz HW; Edwards JE; Dismukes WE;
Clin Infect Dis; 2003 Sep; 37(5):634-43. PubMed ID: 12942393
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study.
Nguyen MH; Peacock JE; Tanner DC; Morris AJ; Nguyen ML; Snydman DR; Wagener MM; Yu VL
Arch Intern Med; 1995 Dec 11-25; 155(22):2429-35. PubMed ID: 7503601
[TBL] [Abstract][Full Text] [Related]
7. The fluconazole era: management of hematogenously disseminated candidiasis in the nonneutropenic patient.
Kramer KM; Skaar DJ; Ackerman BH
Pharmacotherapy; 1997; 17(3):538-48. PubMed ID: 9165556
[TBL] [Abstract][Full Text] [Related]
8. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP
Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780
[TBL] [Abstract][Full Text] [Related]
9. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.
Hachem R; Hanna H; Kontoyiannis D; Jiang Y; Raad I
Cancer; 2008 Jun; 112(11):2493-9. PubMed ID: 18412153
[TBL] [Abstract][Full Text] [Related]
10. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.
Garey KW; Rege M; Pai MP; Mingo DE; Suda KJ; Turpin RS; Bearden DT
Clin Infect Dis; 2006 Jul; 43(1):25-31. PubMed ID: 16758414
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
Horn DL; Neofytos D; Anaissie EJ; Fishman JA; Steinbach WJ; Olyaei AJ; Marr KA; Pfaller MA; Chang CH; Webster KM
Clin Infect Dis; 2009 Jun; 48(12):1695-703. PubMed ID: 19441981
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.
Koh LP; Kurup A; Goh YT; Fook-Chong SM; Tan PH
Am J Hematol; 2002 Dec; 71(4):260-7. PubMed ID: 12447954
[TBL] [Abstract][Full Text] [Related]
13. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
[TBL] [Abstract][Full Text] [Related]
14. Fluconazole plus amphotericin B combinations are not contraindicated and may add benefit for the treatment of candidemia.
Odds FC
Clin Infect Dis; 2003 May; 36(10):1229-31. PubMed ID: 12746766
[No Abstract] [Full Text] [Related]
15. Candida lusitaniae: a cause of breakthrough fungemia in cancer patients.
Minari A; Hachem R; Raad I
Clin Infect Dis; 2001 Jan; 32(2):186-90. PubMed ID: 11170906
[TBL] [Abstract][Full Text] [Related]
16. Anidulafungin versus fluconazole for invasive candidiasis.
Reboli AC; Rotstein C; Pappas PG; Chapman SW; Kett DH; Kumar D; Betts R; Wible M; Goldstein BP; Schranz J; Krause DS; Walsh TJ;
N Engl J Med; 2007 Jun; 356(24):2472-82. PubMed ID: 17568028
[TBL] [Abstract][Full Text] [Related]
17. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group.
Phillips P; Shafran S; Garber G; Rotstein C; Smaill F; Fong I; Salit I; Miller M; Williams K; Conly JM; Singer J; Ioannou S
Eur J Clin Microbiol Infect Dis; 1997 May; 16(5):337-45. PubMed ID: 9228472
[TBL] [Abstract][Full Text] [Related]
18. Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial.
Hamza OJ; Matee MI; Brüggemann RJ; Moshi MJ; Simon EN; Mugusi F; Mikx FH; van der Lee HA; Verweij PE; van der Ven AJ
Clin Infect Dis; 2008 Nov; 47(10):1270-6. PubMed ID: 18840077
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for candidemia-related mortality at a medical center in central Taiwan.
Cheng YR; Lin LC; Young TG; Liu CE; Chen CH; Tsay RW
J Microbiol Immunol Infect; 2006 Apr; 39(2):155-61. PubMed ID: 16604249
[TBL] [Abstract][Full Text] [Related]
20. Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study.
Riedel A; Choe L; Inciardi J; Yuen C; Martin T; Guglielmo BJ
BMC Infect Dis; 2007 Jul; 7():70. PubMed ID: 17605773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
